203 Diagnostic utility of molecular and imaging biomarkers 2 Table 46. Estimated pooled test performance of HBME-1 ICC in indeterminate thyroid nodules ni test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Rossi 2005 37 21 16 37 (100%) 16 5 1 15 46% 94 (71-100) 75 (51-91) 3.76 (1.75-8.12) 0.08 (0.01-0.53) Saggiorato 2005 125 62 63 125 (100%) 60 2 15 48 60% 80 (69-88) 96 (86-100) 20.00 (5.12-78.13) 0.21 (0.13-0.33) Asioli 2010 53 20 33 53 (100%) 17 3 11 22 53% 61 (41-78) 88 (69-97) 5.06 (1.68-15.24) 0.45 (0.28-0.72) Fadda 2011 50 18 32 50 (100%) 10 8 1 31 22% 91 (59-100) 79 (64-91) 4.43 (2.32-8.45) 0.11 (0.02-0.75) Lacoste-Collin 2014 27 4 23 27 (100%) 2 2 0 23 7% 100 (16-100) 92 (74-99) 8.67 (2.40-31.25) 0.18 (0.01-2.32) Addati 2015 76 20 56 68 (89%) 9 8 3 48 16% 75 (43-95) 86 (74-94) 5.25 (2.56-10.78) 0.29 (0.11-0.78) Zhang 2015 51 18 33 51 (100%) 16 2 6 27 43% 73 (50-89) 93 (77-99) 10.55 (2.70-41.15) 0.29 (0.15-0.58) POOLED RESULTS 419 163 256 0 411 (98.1%) 130 30 37 214 39.9% 80.2 (68.7-88.2) 88.1 (81.9-92.4) 6.77 (4.46-10.27) 0.22 (0.14-0.36) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw